Financial Performance Forecast - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -88 million and -72 million RMB, representing an increase in loss of 4.064 million to 20.064 million RMB compared to the previous year, with a year-on-year loss expansion of 5.98% to 29.53%[4] - The projected net loss attributable to shareholders after deducting non-recurring gains and losses for 2024 is expected to be between -93 million and -77 million RMB, indicating an increase in loss of 7.1995 million to 23.1995 million RMB compared to the previous year, with a year-on-year loss expansion of 10.31% to 33.24%[4] - The previous year's net profit attributable to shareholders was -67.936 million RMB, with a total profit of -82.731 million RMB for 2023[5] - The previous year's net profit after deducting non-recurring gains and losses was -69.801 million RMB[5] Revenue Expectations - The company's total revenue for 2024 is expected to be between 140 million and 160 million RMB, remaining roughly stable compared to the previous year[8] Cost Management and Impairment - The company has implemented measures to improve quality and efficiency, resulting in a reduction in expense spending compared to the same period last year[8] - The company has conducted impairment testing on receivables, leading to a significant increase in credit impairment losses based on the aging of receivables[8] Earnings Forecast Reliability - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast[9] - The earnings forecast has not yet been audited by a registered accountant[9] - Investors are advised to pay attention to investment risks as the forecast data is based on preliminary calculations by the company's finance department[10]
兴图新科(688081) - 2024 Q4 - 年度业绩预告